Brophy Michael Burkes sold $1.3M of NTRA

Brophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 5,064 shares of Natera, Inc. (NTRA) at an average of $253.28 ($249.38–$260.49, $1.28M total) across 5 trades over 2026-07-27 to 2026-07-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brophy Michael Burkes
Published Jul 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The only new information is the disclosed sale size, timing, and 10b5-1 status; it does not introduce new fundamentals.

02

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to drive a fundamental repricing by itself.

03

What to watch

The article does not provide context on total insider holdings, option exercises, or whether other insiders sold/bought around the same window.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-29 for sales executed 2026-07-27 to 2026-07-29

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera CFO Brophy Michael Burkes sold about $1.28M of NTRA shares via an open-market sale under a 10b5-1 plan (Form 4).

Expected impact

Likely limited near-term impact; any effect is typically sentiment-only unless paired with other new fundamentals.

Evidence & confidence

The filing is a routine Form 4 open-market sale by the CFO, explicitly under a pre-arranged 10b5-1 plan, with no new guidance, deal, or regulatory action disclosed.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None.

None.

Counterpoint

Because the trades were executed under a 10b5-1 plan, the sale may reflect liquidity planning rather than bearish expectations.

Key entities

  • Natera, Inc.

    Company whose CFO filed the Form 4 insider sale disclosure.

  • Brophy Michael Burkes

    Natera CFO who sold shares in open-market transactions under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.